Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367388 | 0.89 | L3MBTL1 (0.39) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL15607854 | 0.84 | ALDH1A1 (0.39) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL16367389 | 0.84 | ALDH1A1 (0.39) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL16367313 | 0.82 | L3MBTL1 (0.39) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL16367336 | 0.82 | L3MBTL1 (0.38) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL16367393 | 0.80 | L3MBTL1 (0.46) | L3MBTL1PKMALDH1A1TAAR1MAPK1 | |
| SCHEMBL27774814 | 0.78 | ALDH1A1 (0.43) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL27610450 | 0.77 | L3MBTL1 (0.49) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL15608020 | 0.77 | L3MBTL1 (0.46) | L3MBTL1PKMALDH1A1TAAR1KMT2A | |
| SCHEMBL16367396 | 0.77 | L3MBTL1 (0.46) | L3MBTL1PKMALDH1A1TAAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | L3MBTL1 2029/4885PKM 867/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.